Skip to content

Medical Device Stocks: Why Medtech Could Be Undervalued

Thursday, November 19, 2026 · john hopkins

During their recent episode, Taylor, Carlisle, and David Ferreiro discussed Medical Device Stocks: Why Medtech Could Be Undervalued. Here's an excerpt from the episode:

[David]

Yeah. I mean, I started to say this before and we've gotten a little bit more excited outside of biopharma and medical devices recently. And I think it's an interesting thing.

One, I think medtech was on the outs for investors for a long time, especially in the small and mid-cap side. And I think part of that was due to the hype around GLP-1s. We've seen all the benefits and positivity coming out of GLP-1s that seem to hit medtech names the hardest for a lot of different reasons.

One, on the cardiovascular side, there's all this benefit from taking a GLP-1 on cardiovascular outcomes. So there was this thought that anything that was intervening in vessels, the market potential was going to be lower because GLP-1s were this magic cure-all for that. There was also commentary about, there are studies that have shown that GLP-1s reduce basically joint pain, arthritis pain, et cetera.

Therefore, hips and knees don't need to be done anymore. There is obviously an extreme benefit on sleep apnea. So anything that's used to intervene in sleep apnea, that's gone too.

I think that's kind of worn away. I think we've seen, we know that there's a lot of cardiovascular disease that needs to be treated, and there's a lot of other things that need to be treated where there's a lot of great medical device companies out there. Also, interestingly, on the orthopaedic side, we've seen a whole spate of new types of injuries tied to things like paddle.

So maybe as we all lose more weight, we get more active and we have sports-related injuries, not just injuries related to- Couch-related injuries. Yeah, exactly. So what we've seen is, and I give a lot of credit to my colleagues on this one, is real interest in leaning into the medtech side just because they were at historical valuation lows.

We like medtech companies because to be public as a medtech company, for the most part, and there are exceptions to this, they have businesses. Most public investors don't tolerate unprofitable or medical device companies that don't have actual revenues and real business tied to them. Also, we've noticed is, so that's a good thing as a quality investor because we're actually getting a business for what we're buying and not just a dream.

But we've also noticed is that there's two different flavours of medtech companies. There are those that are really high tech that have really deep regulatory modes that really resemble biotech companies. And we lean into those because there's high tech, there's a lot more visibility into the revenue.

There's a lot of the characteristics of the good biotech companies there. So we've been really leaning into those types of companies, names like Oxygen, Veracell, Glaucos, that are great growth businesses with not a lot of competition and they have all of the regulatory protections of those biotechs. We've seen a lot of opportunity there.